Class IIOngoingD-0028-2026
Drug recall · October 22, 2025
Fasenra recall
Why: Lack of Assurance of Sterility:
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30
- Lots / codes
Lot YJ0152, Expiry: 01/31/2028.
- Quantity
- 916 pre-filled syringes
- Company
- Astrazeneca Pharmaceuticals, Gaithersburg, MD
- Distribution
- Nationwide in the U.S
- Initiated
- October 8, 2025 · Voluntary: Firm initiated
- Classified
- October 16, 2025
- Reported
- October 22, 2025
- How notified
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.